MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.
MIP Diagnostics, which produces synthetic antibodies, has launched a new product that could improve the success of rapid sensors in detecting COVID-19. MIP Diagnostics has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs … Continued
MIP Diagnostics Ltd, the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, has announced a collaborative agreement with commercial partners for the co-development and license of a novel MIP-based system with specific applications in the security field. The long-term benefits of the deal could have ground breaking implications in the target applications and generate … Continued